Raja Pramanik1, Sandeep Agarwala2, Yogendra Kumar Gupta3, Sanjay Thulkar4, Sreenivas Vishnubhatla5, Atul Batra1, Deepa Dhawan1, Sameer Bakhshi1. 1. Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India. 2. Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi, India. 3. Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India. 4. Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, India. 5. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India.
Abstract
IMPORTANCE: Although oral metronomic chemotherapy is often used in progressive pediatric solid malignant tumors, a literature review reveals that only small single-arm retrospective or phase 1 and 2 studies have been performed. Skepticism abounds because of the lack of level 1 evidence. OBJECTIVES: To compare the effect of metronomic chemotherapy on progression-free survival (PFS) with that of placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: A double-blinded, placebo-controlled randomized clinical trial was conducted from October 1, 2013, through December 31, 2015, at the cancer center at All India Institute of Medical Sciences in children aged 5 to 18 years with primary extracranial, nonhematopoietic solid malignant tumors that progressed after at least 2 lines of chemotherapy and had no further curative options. INTERVENTIONS: One arm received a 4-drug oral metronomic regimen of daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide, whereas the other arm received placebo. Disease status was assessed at baseline, 9 weeks, 18 weeks, and 27 weeks or at clinical progression. MAIN OUTCOMES AND MEASURES: The primary end point was PFS as defined by the proportion of patients without disease progression at 6 months, and PFS duration and overall survival (OS) were secondary end points. RESULTS: A total of 108 of the 123 patients screened were enrolled, with 52 randomized to the placebo group (median age, 15 years; 40 male [76.9%]) and 56 to the metronomic chemotherapy group (median age, 13 years; 42 male [75.0%]). At a median follow-up of 2.9 months, 100% of the patients had disease progression by 6 months in the placebo group vs 96.4% in the metronomic chemotherapy group (P = .24). Median PFS and OS in the 2 groups was similar (hazard ratio [HR], 0.69; 95% CI, 0.47-1.03 [P = .07] for PFS; and HR, 0.74; 95% CI, 0.50-1.09 [P = .13] for OS). In post hoc subgroup analysis, cohorts receiving more than 3 cycles (HR for PFS, 0.46; 95% CI, 0.23-0.93; P = .03) and those without a bone sarcoma (ie, neither primitive neuroectodermal tumor nor osteosarcoma) (HR for PFS, 0.39; 95% CI, 0.18-0.81; P = .01) appeared to benefit from metronomic chemotherapy. CONCLUSIONS AND RELEVANCE: Metronomic chemotherapy does not improve 6-month PFS, compared with placebo, among pediatric patients with extracranial progressive solid malignant tumors . However, patients without bone sarcoma and those able to tolerate therapy for more than 3 cycles (9 weeks) benefit. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01858571.
IMPORTANCE: Although oral metronomic chemotherapy is often used in progressive pediatric solid malignant tumors, a literature review reveals that only small single-arm retrospective or phase 1 and 2 studies have been performed. Skepticism abounds because of the lack of level 1 evidence. OBJECTIVES: To compare the effect of metronomic chemotherapy on progression-free survival (PFS) with that of placebo in pediatric patients with primary extracranial, nonhematopoietic solid malignant tumors that progress after at least 2 lines of chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: A double-blinded, placebo-controlled randomized clinical trial was conducted from October 1, 2013, through December 31, 2015, at the cancer center at All India Institute of Medical Sciences in children aged 5 to 18 years with primary extracranial, nonhematopoietic solid malignant tumors that progressed after at least 2 lines of chemotherapy and had no further curative options. INTERVENTIONS: One arm received a 4-drug oral metronomic regimen of daily celecoxib and thalidomide with alternating periods of etoposide and cyclophosphamide, whereas the other arm received placebo. Disease status was assessed at baseline, 9 weeks, 18 weeks, and 27 weeks or at clinical progression. MAIN OUTCOMES AND MEASURES: The primary end point was PFS as defined by the proportion of patients without disease progression at 6 months, and PFS duration and overall survival (OS) were secondary end points. RESULTS: A total of 108 of the 123 patients screened were enrolled, with 52 randomized to the placebo group (median age, 15 years; 40 male [76.9%]) and 56 to the metronomic chemotherapy group (median age, 13 years; 42 male [75.0%]). At a median follow-up of 2.9 months, 100% of the patients had disease progression by 6 months in the placebo group vs 96.4% in the metronomic chemotherapy group (P = .24). Median PFS and OS in the 2 groups was similar (hazard ratio [HR], 0.69; 95% CI, 0.47-1.03 [P = .07] for PFS; and HR, 0.74; 95% CI, 0.50-1.09 [P = .13] for OS). In post hoc subgroup analysis, cohorts receiving more than 3 cycles (HR for PFS, 0.46; 95% CI, 0.23-0.93; P = .03) and those without a bone sarcoma (ie, neither primitive neuroectodermal tumor nor osteosarcoma) (HR for PFS, 0.39; 95% CI, 0.18-0.81; P = .01) appeared to benefit from metronomic chemotherapy. CONCLUSIONS AND RELEVANCE: Metronomic chemotherapy does not improve 6-month PFS, compared with placebo, among pediatric patients with extracranial progressive solid malignant tumors . However, patients without bone sarcoma and those able to tolerate therapy for more than 3 cycles (9 weeks) benefit. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01858571.
Authors: Raul C Ribeiro; Eva Steliarova-Foucher; Ian Magrath; Jean Lemerle; Tim Eden; Caty Forget; Isabel Mortara; Isabelle Tabah-Fisch; Jose Julio Divino; Thomas Miklavec; Scott C Howard; Franco Cavalli Journal: Lancet Oncol Date: 2008-08 Impact factor: 41.316
Authors: Jaroslav Sterba; Dalibor Valik; Peter Mudry; Tomas Kepak; Zdenek Pavelka; Viera Bajciova; Karel Zitterbart; Vera Kadlecova; Pavel Mazanek Journal: Onkologie Date: 2006-07-03
Authors: L Mi Rim Choi; Brian Rood; Naynesh Kamani; Deborah La Fond; Roger J Packer; Maria Rita Santi; Tobey J Macdonald Journal: Pediatr Blood Cancer Date: 2008-05 Impact factor: 3.167
Authors: Nathan J Robison; Federico Campigotto; Susan N Chi; Peter E Manley; Christopher D Turner; Mary Ann Zimmerman; Christine A Chordas; Annette M Werger; Jeffrey C Allen; Stewart Goldman; Joshua B Rubin; Michael S Isakoff; Wilbur J Pan; Ziad A Khatib; Melanie A Comito; Anne E Bendel; Jay B Pietrantonio; Laura Kondrat; Shannon M Hubbs; Donna S Neuberg; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2013-10-04 Impact factor: 3.167
Authors: Jeffrey B West; Mina N Dinh; Joel S Brown; Jingsong Zhang; Alexander R Anderson; Robert A Gatenby Journal: Clin Cancer Res Date: 2019-04-16 Impact factor: 12.531
Authors: Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Tobias Pukrop; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle Journal: Int J Mol Sci Date: 2018-11-09 Impact factor: 5.923
Authors: Daniel Heudobler; Michael Rechenmacher; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Simone Thomas; Tobias Pukrop; Christina Hackl; Wolfgang Herr; Lina Ghibelli; Christopher Gerner; Albrecht Reichle Journal: Front Pharmacol Date: 2018-11-28 Impact factor: 5.810